Dupont A G, Van der Niepen P, Volckaert A, Ingels M, Bossuyt A M, Jonckheer M H, Six R O
Department of Internal Medicine, University Hospital, Free University Brussels, Belgium.
J Cardiovasc Pharmacol. 1987;10 Suppl 7:S148-50. doi: 10.1097/00005344-198706107-00032.
The effect of the converting enzyme inhibitor lisinopril on renal and cardiac hemodynamics was studied in patients with moderate to severe primary hypertension, in a multicenter, double-blind, randomized clinical trial comparing the antihypertensive effect of lisinopril (LIS) and nifedipine (NIF). After a 2 week placebo run-in period, 15 patients were randomized in a 2:1 ratio to receive either LIS (20-80 mg q.d., n = 10) or NIF (20-40 mg b.i.d., n = 5). LIS significantly reduced blood pressure (BP) without changing heart rate or cardiac output. LIS significantly increased renal blood flow; glomerular filtration rate (GFR) was not changed. It can be concluded that LIS is an effective antihypertensive agent with a favorable renal hemodynamic profile.
